Adversity is less terrifying than hope: Maravai LifeSciences Holdings Inc. (MRVI)

Maravai LifeSciences Holdings Inc. (NASDAQ: MRVI) stock jumped 2.33% on Friday to $26.31 against a previous-day closing price of $25.71. With 1.25 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.36 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $26.92 whereas the lowest price it dropped to was $26.00. The 52-week range on MRVI shows that it touched its highest point at $63.55 and its lowest point at $23.05 during that stretch. It currently has a 1-year price target of $42.88.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of MRVI was up-trending over the past week, with a rise of 3.46%, but this was down by -10.27% over a month. Three-month performance dropped to -12.68% while six-month performance fell -11.62%. The stock lost -44.87% in the past year, while it has lost -37.21% so far this year. A look at the trailing 12-month EPS for MRVI yields 1.81 with Next year EPS estimates of 1.23. For the next quarter, that number is 0.45. This implies an EPS growth rate of 422.90% for this year and -33.22% for next year.

Float and Shares Shorts:

At present, 131.49 million MRVI shares are outstanding with a float of 89.04 million shares on hand for trading. On Jul 14, 2022, short shares totaled 6.0 million, which was 4.56% higher than short shares on Jun 14, 2022. In addition to Mr. Carl W. Hull as the firm’s Co-Founder, Chairman & CEO, Mr. Kevin M. Herde serves as its Exec. VP & CFO.

Institutional Ownership:

Through their ownership of 103.15% of MRVI’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 43.61% of MRVI, in contrast to 39.10% held by mutual funds. Shares owned by individuals account for 16.85%. As the largest shareholder in MRVI with 14.52% of the stake, Select Equity Group LP holds 19,100,056 shares worth 19,100,056. A second-largest stockholder of MRVI, The Vanguard Group, Inc., holds 10,361,833 shares, controlling over 7.88% of the firm’s shares. Massachusetts Financial Services is the third largest shareholder in MRVI, holding 8,965,103 shares or 6.82% stake. With a 2.50% stake in MRVI, the Vanguard Total Stock Market Index is the largest stakeholder. A total of 3,289,480 shares are owned by the mutual fund manager. The MFS Mid Cap Growth Fund, which owns about 2.48% of MRVI stock, is the second-largest Mutual Fund holder. It holds 3,261,893 shares valued at 92.67 million. Vanguard Small Cap Index Fund holds 2.15% of the stake in MRVI, owning 2,826,240 shares worth 80.29 million.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Mar 30, 2022, MRVI reported revenue of $244.29M and operating income of $167.37M. Over the past year, revenue came in at $895.32M while operating income stood at $630.82M. It generated $66.86M net income for the quarter, which came to $225.80M over the last twelve months. The EBITDA in the recently reported quarter was $174.75M and diluted EPS was $0.50. EBITDA for the full year was $645.69M.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for MRVI since 9 analysts follow the stock currently. There are 8 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 1 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With MRVI analysts setting a high price target of $49.00 and a low target of $35.00, the average target price over the next 12 months is $42.88. Based on these targets, MRVI could surge 86.24% to reach the target high and rise by 33.03% to reach the target low. Reaching the average price target will result in a growth of 62.98% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. MRVI will report FY 2022 earnings on 02/28/2023. Analysts have provided yearly estimates in a range of $1.88 being high and $1.80 being low. For MRVI, this leads to a yearly average estimate of $1.84. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Maravai LifeSciences Holdings Inc. surprised analysts by $0.10 when it reported $0.54 EPS against a consensus estimate of $0.44. The surprise factor in the prior quarter was $0.07. Based on analyst estimates, the high estimate for the next quarter is $0.48 and the low estimate is $0.39. The average estimate for the next quarter is thus $0.45.

Summary of Insider Activity:

Insiders traded MRVI stock several times over the past three months with 1 Buys and 0 Sells. In these transactions, 63,498 shares were bought while 0 shares were sold. The number of buy transactions has increased to 27 while that of sell transactions has risen to 6 over the past year. The total number of shares bought during that period was 263,495 while 22,583,715 shares were sold.

Leave a Comment

Your email address will not be published.